Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Although cost-utility models are often used to estimate the value of treatments for metastatic cancer, limited information is available on the utility of common treatment modalities. Bisphosphonate treatment for bone metastases is frequently administered via intravenous infusion, while a newer treatment is administered as a subcutaneous injection. This study estimated the impact of these treatment modalities on health state preference. METHODS: Participants from the UK general population completed time trade-off interviews to assess the utility of health state vignettes. Respondents first rated a health state representing cancer with bone metastases. Subsequent health states added descriptions of treatment modalities (ie, injection or infusion) to this basic health state. The two treatment modalities were presented with and without chemotherapy, and infusion characteristics were varied by duration (30 minutes or 2 hours) and renal monitoring. RESULTS: A total of 121 participants completed the interviews (52.1% female, 76.9% white). Cancer with bone metastases had a mean utility of 0.40 on a standard utility scale (1 = full health; 0 = dead). The injection, 30-minute infusion, and 2-hour infusion had mean disutilities of -0.004, -0.02, and -0.04, respectively. The mean disutility of the 30-minute infusion was greater with renal monitoring than without. Chemotherapy was associated with substantial disutility (-0.17). When added to health states with chemotherapy, the mean disutilities of injection, 30-minute infusion, and 2-hour infusion were -0.02, -0.03, and -0.04, respectively. The disutility associated with injection was significantly lower than the disutility of the 30-minute and 2-hour infusions (P < 0.05), regardless of chemotherapy status. CONCLUSION: Respondents perceived an inconvenience with each type of treatment modality, but injections were preferred over infusions. The resulting utilities may be used in cost-utility models examining the value of treatments for the prevention of skeletal-related events in patients with bone metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490 · cited 1×
“Health state B included four statements designed to represent injection procedures for denosumab.(9,10,12,30)”
MethodSafety of intravenous and oral bisphosphonates and compliance with dosing regimens
Conte, P., & Guarneri, V. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-28 · Cited by 241 · cited 1×
“During the telephone interviews, the four clinicians agreed with published literature suggesting that blood draws were required for renal monitoring prior to the administration of bisphosphonates.(8,37) However, opinions varied on whether blood draws occurred more commonly on the same day as the bisphosphonate infusio…”
Background
Cited by
Olofsson, S., Norrlid, H., Karlsson, E., Wilking, U., & Ragnarson Tennvall, G. (2016) · The Breast · doi:10.1016/j.breast.2016.07.008 · Cited by 45
Aguiar-Ibáñez, R., Fotheringham, I., Mittal, L., Sillah, A., & Pathak, S. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02985-9 · Cited by 19
Body, J.-J., Gatta, F., De Cock, E., Tao, S., Kritikou, P., Wimberger, P., Mebis, J., Peeters, M., Pedrazzoli, P., Caraceni, A., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3697-5 · Cited by 11
Metadata
- Authors
- Matza, L., Cong, Chung, Stopeck, A., Tonkin, K., Brown, Braun, Brunt, V., & McDaniel, K.
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2013-08
- Volume
- 7
- Pages
- 855
- ISSN
- 1177-889X (ISSN-L)
- OpenAlex
- W2146155626
- Cited by
- 38
- References
- 3
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. https://app.cochat.ai/papers/10.2147/ppa.s44947
- The paper
- Matza, L., Cong, Chung, Stopeck, A., Tonkin, K., Brown, Braun, Brunt, V., & McDaniel, K. (2013). Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Preference and Adherence. https://doi.org/10.2147/ppa.s44947
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.